Catalyst Event
BioNTech SE (BNTX) · Other
From KEDI U.S. Medical AI Index (KUSMAI)
5/30/2026, 12:00:00 AM
Announced encouraging interim Phase 2 data for its investigational lung cancer treatment, pumitamig, on 2026-05-30, showing high response rates in non-small cell lung cancer (NSCLC). High importance is estimated based on the significant clinical impact of Phase 2 oncology data.
Korean Translation
2026년 5월 30일, 비소세포폐암(NSCLC)에서 높은 반응률을 보인 폐암 치료제 후보물질 푸미타미그(pumitamig)의 긍정적인 임상 2상 중간 데이터를 발표함. 임상 2상 항암 데이터의 유의미한 임상적 영향을 고려하여 높은 중요도로 예상됨.
Related Recent Events
Tempus AI Inc (TEM) · Earnings Release
Tempus AI is scheduled to report its Q2 2026 financial results; earnings releases typically result in price moves of 5% or more, scheduled.
8/14/2026, 12:00:00 AM
BioNTech SE (BNTX) · Earnings Release
Next earnings release for Q2 2026 on 2026-08-03 is scheduled. Low importance is estimated for the scheduling announcement itself.
8/3/2026, 12:00:00 AM
AbbVie Inc (ABBV) · Earnings Release
Q2 2026 earnings release for 2026-07-30. Low importance as it is a routine announcement scheduled.
7/30/2026, 12:00:00 AM
Alphabet Inc (GOOGL) · Earnings Release
Alphabet's Q2 2026 earnings release is scheduled.
7/28/2026, 12:00:00 AM
Intuitive Surgical Inc (ISRG) · Earnings Release
Intuitive Surgical's Q2 2026 earnings release, a major stock catalyst, is scheduled.
7/21/2026, 12:00:00 AM
Recursion Pharmaceauticals Inc (RXRX) · Other
2026 Annual Meeting of Stockholders scheduled for June 17, 2026. Market reaction not yet occurred; low importance assigned due to likely <5% price impact from annual meeting scheduled.
6/17/2026, 12:00:00 AM